SCHEMBL40761

SCHEMBL40761

Cn1c(=O)cc[nH]c1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27983204 1.00 BRD4 (0.41)
Cyclohexane SCHEMBL27414669 0.93 LMNA (0.42)
SCHEMBL28561589 0.89 BRD4 (0.35)
SCHEMBL28086415 0.82 BRD4 (0.31)
SCHEMBL28555227 0.78 GPR84 (0.43)
SCHEMBL21917363 0.76
SCHEMBL297038 0.76
SCHEMBL9443405 0.74 CRBN (0.35)
SCHEMBL4348692 0.73 ADRA1D (0.37)
SCHEMBL9118472 0.72 KDM4E (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 5997 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026099316-A1 COMPOUNDS AND METHODS FOR REDUCING ARHGEF6 EXPRESSION ASTRAZENECA AB (SE) 2026-05-15 WO claimed
US-20260109977-A1 MODIFIED RNA FOR INCREASING PROTEIN EXPRESSION TRILINK BIOTECHNOLOGIES, LLC (US) 2026-04-23 US claimed
EP-4617375-A2 METHODS, COMPOSITIONS AND SYSTEMS FOR IMPROVING THE BINDING OF METHYLATED POLYNUCLEOTIDES Guardant Health, Inc. (US) 2025-09-17 EP claimed
CN-120054582-A Mono-atom catalyst for denitration and sulfur resistance and preparation method thereof 福州大学 2025-05-30 CN claimed
EP-4065725-B1 METHODS, COMPOSITIONS AND SYSTEMS FOR IMPROVING THE BINDING OF METHYLATED POLYNUCLEOTIDES GUARDANT HEALTH INC (US) 2025-05-21 EP claimed
US-12281138-B2 5′-cap-trinucleotide- or higher oligonucleotide compounds and their use in stabilizing RNA, expressing proteins in therapy BIONTECH RNA PHARMACEUTICALS GMBH (DE) 2025-04-22 US claimed
WO-2025068896-A1 COMPOUNDS AND METHODS FOR REDUCING PSD3 EXPRESSION ASTRAZENECA AB (SE) 2025-04-03 WO claimed
US-20250066828-A1 C-NUCLEOSIDE MONOPHOSPHATE SYNTHESIS ENGINZYME AB (SE) 2025-02-27 US claimed
EP-4463560-A1 C-NUCLEOSIDE MONOPHOSPHATE SYNTHESIS Uab Biomatter Designs (LT) 2024-11-20 EP claimed
CN-118772068-A Preparation method of deuterated methyl uric acid standard substance 上海原思标物科技有限公司 2024-10-15 CN claimed
CN-1236315-A A pharmaceutical composition containing kynurenine and thymine or tryptophan and thymine PAUL HUBER (BR) 1999-11-24 CN claimed
CN-1043769-C L-nucleosides for treating hepatitis B virus and Epstein-Barr virus and uses thereof UNIV GEORGIA (US) 1999-06-23 CN claimed
US-5891684-A RIBOZYMES RIBOZYME PHARMACEUTICALS, INC. (US) 1999-04-06 US claimed
EP-0799313-A2 METHOD AND REAGENT FOR TREATMENT OF ARTHRITIC CONDITIONS, INDUCTION OF GRAFT TOLERANCE AND REVERSAL OF IMMUNE RESPONSES RIBOZYME PHARMACEUTICALS, INC. (US) 1997-10-08 EP claimed
US-5672501-A Base-modified enzymatic nucleic acid RIBOZYME PHARMACEUTICALS, INC. (US) 1997-09-30 US claimed
CN-1143966-A L-nucleosides for the treatment of hepatitis B virus and Epstein-Barr virus UNIV GEORGIA (US) 1997-02-26 CN claimed
WO-1996018736-A2 METHOD AND REAGENT FOR TREATMENT OF ARTHRITIC CONDITIONS, INDUCTION OF GRAFT TOLERANCE AND REVERSAL OF IMMUNE RESPONSES RIBOZYME PHARMACEUTICALS, INC. (US) 1996-06-20 WO claimed
CN-1013076-B PROCESS FOR PREPARING HETEROCYCLIC COMPOUNDS HOFFMANN LA ROCHE (CH) 1991-07-10 CN claimed
CN-86101792-A The preparation method of heterogeneous ring compound 1986-11-12 CN claimed
WO-1983002891-A1 URACIL DERIVATIVES AS ANTI-SEBORRHEIC ADDITIVES FOR COSMETIC PRODUCTS Möller, Hinrich 1983-09-01 WO claimed